Bachy, Emmanuel http://orcid.org/0000-0003-2694-7510
Le Gouill, Steven
Di Blasi, Roberta
Sesques, Pierre
Manson, Guillaume
Cartron, Guillaume
Beauvais, David http://orcid.org/0000-0003-1866-828X
Roulin, Louise
Gros, François Xavier
Rubio, Marie Thérèse
Bories, Pierre
Bay, Jacques Olivier
Llorente, Cristina Castilla
Choquet, Sylvain http://orcid.org/0000-0002-7791-0470
Casasnovas, René-Olivier
Mohty, Mohamad
Guidez, Stéphanie
Joris, Magalie
Loschi, Michaël http://orcid.org/0000-0002-4460-5939
Carras, Sylvain
Abraham, Julie
Chauchet, Adrien
Drieu La Rochelle, Laurianne
Deau-Fischer, Bénédicte
Hermine, Olivier
Gastinne, Thomas
Tudesq, Jean Jacques http://orcid.org/0000-0003-4879-8106
Gat, Elodie
Broussais, Florence
Thieblemont, Catherine http://orcid.org/0000-0002-9941-2448
Houot, Roch
Morschhauser, Franck
Article History
Received: 29 March 2022
Accepted: 26 July 2022
First Online: 22 September 2022
Competing interests
: The authors report the following competing interests: E.B.: consulting fees or honoraria from Novartis, Kite/Gilead, Roche, Takeda and Incyte; research funding (paid to institution) from Amgen; and travel and personal fees from Roche and Incyte. S.L.G.: honoraria from Janssen-Cilag, Kite/Gilead and Novartis. P.S.: honoraria or consultancy form Chugaï, Bristol Myers Squibb, Novartis and Kite/Gilead. T.G.: honoraria from Kite/Gilead, Pfizer and Takeda. S.G.: honoraria from Kite/Gilead, Incyte, Takeda and Janssen. P.B.: honoraria from Bristol Myers Squibb, Kite/Gilead, Novartis and Abbvie. R.H.: honoraria from Bristol Myers Squibb, Kite/Gilead, Incyte, Janssen, Merck Sharp & Dohme, Takeda, Novartis and Roche. F.M.: consulting fees or honoraria from Genmab, Novartis, Kite/Gilead, Bristol Myers Squibb, AstraZeneca, Epizyme, Roche, Abbvie, Chugaï, Janssen, Incyte, Kymera, Miltenyi and Roche; and expert testimony for Roche. O.H.: consultancy for AB Science and Inatherys; and research funding (paid to institution) from Bristol Myers Squibb and Alexion. G.C.: consulting fees and honoraria from Roche, Bristol Myers Squibb, Onwards Therapeutics, MedxCell, EmerCell, MabQ, Sanofi, Abbvie, Takeda, Roche, Janssen, Roche, Novartis and Myltenyi. M.L.: honoraria or travel grants from Pfizer, Novartis, Gilead and Bristol Myers Squibb. R.O.C.: consultancy and honoraria from Roche, Takeda, Bristol Myers Squibb, Merck, Kite/Gilead, Abbvie and ADC Therapeutics; and research funding from Roche, Takeda and Kite/Gilead. J.A.: consulting fees and honoraria from Roche and Janssen-Cilag; S.C.: consulting fees and honoraria from Abbvie, AstraZeneca, Novartis, Janssen, Takeda, Atara, Pierre Fabre, Kite/Gilead and Viatris. C.C.L.: honoraria from Kite/Gilead; D.B.: honoraria from Kite/Gilead. J.J.T.: consulting fees and honoraria from Bristol Myers Squibb and Kite/Gilead. M.M.: consulting fees and honoraria from Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Janssen, Takeda, Novartis and Sanofi; and research funding from Bristol Myers Squibb, Janssen and Sanofi; F.X.G.: honoraria from Bristol Myers Squibb, Novartis and Kite/Gilead; L.D.L.R.: honoraria from Kite/Gilead; M.T.R.: honoraria from Novartis and Kite/Gilead. C.T.: consulting fees and honoraria from Novartis, Bristol Myers Squibb, Bayer, Abbvie, Gilead Sciences, Roche, Janssen, Kite, Incyte and Amgen; and educational activities for Janssen, Roche, Bristol Myers Squibb and Novartis. R.D.B.: honoraria, consulting and personal fees from Janssen, Pfizer, Bristol Myers Squibb, Kite/Gilead and Novartis.